Perry Jennifer Scott, the Chief Operating Officer of Bicycle Therapeutics PLC, has amended a previous filing related to the sale of ordinary shares. This amendment, filed on October 7, 2026, aims to clarify discrepancies in the original report regarding the number of shares sold and their weighted average price. Such updates are crucial for maintaining transparency with shareholders and the investing public.
Bicycle Therapeutics PLC, a company focused on developing innovative therapies, is categorized under the pharmaceutical preparations industry. The company is based in Cambridge, UK, and operates under the ticker symbol BCYC. Recent filings indicate ongoing activity in the company's stock transactions, reflecting its commitment to keeping stakeholders informed.
The filing reveals that Scott sold a total of 356 ordinary shares on October 5, 2026. The amended report specifies that the original Form 4 mistakenly overstated the number of shares sold and the weighted average price, which has now been corrected. The weighted average price for the shares sold was reported to be between $3.56 and $3.78.
This update may affect shareholders and potential investors, as accurate reporting is essential for informed decision-making. The filing emphasizes that the share sales were executed to cover statutory tax withholding obligations related to the vesting of restricted stock units (RSUs), ensuring compliance with tax regulations.
Looking ahead, it remains to be seen if further updates will be filed as Bicycle Therapeutics continues its operations and engages with its shareholders. The filing does not specify any future actions following this amendment.